Dmitrij Hristodorov
Directeur/Bestuurslid bij Complement Therapeutics Ltd.
Profiel
Dmitrij is a Partner in the Munich office and joined the Forbion team in 2020.
Prior to joining Forbion, Dmitrij was Senior Director of Global Business Development & Licensing at Bayer Pharma where he was mainly responsible for Ophthalmology, Cardiology, Nephrology and Pulmonology.
His spectrum of activities included scouting, evaluation, negotiation and transaction for in- and out-licensing.
Before joining the Business Development Group at Bayer Pharma, Dmitrij spent two years in R&D where he was Head of Pharmacology Lab in Ophthalmology.
His role encompassed activities ranging from target discovery to start of preclinical development.
Dmitrij received his PhD in Immunology (summa cum laude) from the University of Aachen/Fraunhofer IME in 2013.
Actieve functies van Dmitrij Hristodorov
| Bedrijven | Functie | Begin |
|---|---|---|
| Forbion Capital Partners Germany GmbH | Private Equity Investor | 01-01-2021 |
Oxular Ltd.
 Oxular Ltd. BiotechnologyHealth Technology Oxular Ltd. engages in research and experimental development on biotechnology. The firm develops retinal treatments to access specific small spaces in the eye and to provide drug distribution to tissues involved in retinal diseases. The company was founded by Tom Cavanagh and Ronald K. Yamamoto in 2014 and is headquartered in Oxford, the United Kingdom. | Directeur/Bestuurslid | 01-03-2021 |
Complement Therapeutics Ltd.
 Complement Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Complement Therapeutics Ltd. develops medicines that target the complement system. The British company was founded by Richard Unwin, Simon J. Clark, and Paul Bishop. The CEO is Rafiq Hasan. | Directeur/Bestuurslid | - |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Private Equity Investor | 01-09-2021 |
Opleiding van Dmitrij Hristodorov
| RWTH Aachen University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
| Forbion Capital Partners Germany GmbH | Finance |
Oxular Ltd.
Oxular Ltd. BiotechnologyHealth Technology Oxular Ltd. engages in research and experimental development on biotechnology. The firm develops retinal treatments to access specific small spaces in the eye and to provide drug distribution to tissues involved in retinal diseases. The company was founded by Tom Cavanagh and Ronald K. Yamamoto in 2014 and is headquartered in Oxford, the United Kingdom. | Health Technology |
Complement Therapeutics Ltd.
Complement Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Complement Therapeutics Ltd. develops medicines that target the complement system. The British company was founded by Richard Unwin, Simon J. Clark, and Paul Bishop. The CEO is Rafiq Hasan. | Health Technology |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Finance |